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Purpose: Prostate biopsy is often recommended based on increases in prostate
specific antigen and/or abnormal digital rectal examination. We investigated
the stability of a single positive test during the next 3 consecutive years.
Materials and Methods: A total of 2,578 participants in a San Antonio screen-
ing cohort with 2 or more consecutive annual prostate specific antigen and
digital rectal examination tests were identified. Occurrences of an increased
prostate specific antigen (2.5 ng/ml or greater) followed by 1 or more nonin-
creased prostate specific antigen results were compared with similar fluctu-
ations of digital rectal examination from abnormal to normal.
Results: In 2,272 men who did not have a biopsy during the study, in 23.3% of
744 incidences of an increased prostate specific antigen with 1 year of fol-
lowup, the next prostate specific antigen was not increased. In 19.5% of 462
incidences of an increased prostate specific antigen with 2 years of followup,
the next 2 consecutive prostate specific antigen levels were not increased.
Finally, in 17.5% of 285 incidences of an increased prostate specific antigen
with 3 years of followup, the next 3 consecutive prostate specific antigens were
not increased. Rates were similar but lower in 221 men with 1 or more
negative biopsies during the study and in 85 men in whom prostate cancer
eventually developed during the study. In contrast, approximately 70% of
abnormal digital rectal examinations were normal the following year even in
patients with prostate cancer, and in the majority of incidences remained
normal the next 2 to 3 consecutive years.
Conclusions: Occurrences of reversed prostate specific antigen cut point or
abnormal digital rectal examination based decisions to biopsy 1 or more years
after the initial test are not uncommon, suggesting repetition of these tests.
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2393.PROSTATE specific antigen in serum
and digital rectal examination are the
most commonly used tools for screen-
ing for prostate cancer.1 The wide-
spread use of PSA and DRE have
resulted in a dramatic increase in
prostate cancer detection in the last
decade.2 While the rate of detection of
organ confined disease has increased
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ability, there has been an undisputed
increase in the detection of clinically
insignificant cancers subjected to un-
necessary treatment and related mor-
bidity.3 The use of PSA and DRE for
screening in prostate cancer detection
has been a subject of relentless de-
bate.4 Outcomes regarding potential
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YEARLY VARIATION IN PROSTATE SPECIFIC ANTIGEN2072benefits of screening will not be known until the
results of the ongoing Prostate, Lung, Colorectal and
Ovarian Cancer trial in the United States and the
European Randomized Study of Screening for Pros-
tate Cancer in Europe are reported.5,6 Both screen-
ing tests have been used in a dichotomous manner in
clinical practice. Patients are generally advised to
undergo prostate biopsy if PSA exceeds a cutoff of
2.5 or 4.0 ng/ml, or if DRE is abnormal. Recent
reports have suggested caution while recommending
prostate biopsy based on a single increased PSA.7
While natural biological variation occurs in PSA
testing in the short term, year-to-year fluctuations
in serum PSA have also been reported in unscreened
populations.7,8 Transrectal ultrasound guided bi-
opsy of the prostate, although technically simple, is
an invasive procedure that may lead to significant
bleeding and infection related complications.9 In
this study we evaluated the year-to-year changes in
serum PSA and DRE findings in a prospectively
studied cohort based on biopsy recommendations
and biopsy findings.
MATERIALS AND METHODS
The San Antonio Center of Biomarkers of Risk for Pros-
tate Cancer is a Clinical and Epidemiological Validation
Center of the Early Detection Research Network of the
National Cancer Institute. Since 2000 SABOR has re-
cruited 3,651 men without a diagnosis of prostate can-
cer into a longitudinal followup study. Participants
have been followed annually by their SABOR affiliated
clinician with DRE and PSA measurement. The SABOR
clinicians are credentialed to perform DRE and are
approved by the institutional review board to perform
it. They perform the DRE blinded to the PSA result
since the serum for PSA testing is only sampled at the
visit and determined at a central laboratory later. After
each annual visit prostate biopsy is offered to patients
with a PSA of 2.5 ng/ml or more, an abnormal DRE
suspicious for prostate cancer or, in some circum-
stances, a positive family history of prostate cancer.
SABOR participants with 2 or more annual PSA mea-
surements available were stratified into 3 groups accord-
ing to whether they had undergone prostate biopsy during
the followup of 1) no biopsy, 2) 1 or more negative biopsies,
or 3) prostate cancer diagnosis. The latter 2 groups were
kept distinct. The prostate cancer group included those
who had prior negative biopsies but this number was
small (6 had 1 prior biopsy, 3 had 2). Only PSA values
before prostate cancer diagnosis were included in the
analysis. Nonparametric Wilcox tests were used for pair-
wise comparison of continuous outcomes and covariates
among the 3 groups. For categorical summaries the chi-
square test was used. All statistical tests were at the  
0.05 (2-sided) level of statistical significance and all sta-
tistical analyses were performed using the R statistical
package (version 2.6.0, R Foundation for Statistical Com-
puting, 2007).RESULTS
Of 3,095 men under annual followup in SABOR
2,578 had 2 or more PSA values and were eligible for
analysis. Study participants were assigned to 1 of 3
categories of 1) those without prostate biopsy during
followup (2,272, 88.1%), 2) those with 1 or more
prostate biopsies, all negative for prostate cancer
(221, 8.6%), and 3) those with biopsy detected pros-
tate cancer (85, 3.3%, table 1). Participants without
prostate biopsy were statistically significantly
younger than those who had a prior negative bi-
opsy or those diagnosed with prostate cancer (both
p 0.0001), had lower rates of a family history of
prostate cancer than participants with a prior neg-
ative biopsy or cancer diagnosis (both p 0.0001)
and were more ethnically mixed than participants
with a prior negative biopsy (p  0.01). There were
no statistically significant differences in any of these
characteristics between participants with prior neg-
ative biopsies and those with a prostate cancer di-
agnosis. All 3 groups differed significantly from each
other in terms of the cumulative number of years of
followup (including number of annual PSA measure-
ments available). Cancer cases had the least cumu-
lative followup (maximum of 5 years), followed by
the group with no biopsy and the group with 1 or
more prior biopsies (all p 0.0001). The last 2
groups had a substantial fraction of subjects fol-
lowed for 5 years. All 3 groups differed significantly
from each other in terms of number of abnormal
tests (DRE or PSA 2.5 ng/ml or greater) per person,
with the prior negative biopsy and prostate cancer
groups having a greater number of abnormal tests
(all p 0.02).
Observed fluctuations of the PSA test after an
increase of 2.5 ng/ml or greater are shown in table 2.
In the majority of incidences an increased PSA was
followed by consecutive increased PSAs 1, 2 and
even 3 consecutive years later. However, in not in-
significant proportions of cases the next consecutive
annual PSAs reverted to a status of not increased
and remained there. In men who never had a biopsy
performed during the study in 23.3% of incidences
the next PSA was not increased, in 19.5% the next 2
consecutive PSAs were not increased and in 17.5%
the next 3 consecutive PSAs were not increased.
Notably the tendency of an increased PSA to revert
to not increased at the next visit did not substan-
tially decrease with higher PSA. In men with no
biopsy performed, for increased PSA in the ranges of
2.5 to 4.0, 4.0 to 6.0, 6.0 to 10.0 and greater than 10.0
ng/ml, the fractions of time the next annual PSA was
not increased were 27.9%, 14.6%, 9.7% and 26.7%,
respectively (in 499, 158, 72 and 15 incidences, re-
spectively). Persistence of an increased PSA during
the ensuing 1 to 3 years more commonly occurred in
YEARLY VARIATION IN PROSTATE SPECIFIC ANTIGEN 2073men with 1 or more negative biopsies performed
during study or with an eventual prostate cancer
diagnosis (p 0.03 for comparisons of these groups
to the no biopsy group). Median (range) increased
PSAs among the no biopsy, 1 or more negative bi-
opsy and prostate cancer groups were 3.3 (2.5 to
29.8), 4.1 (2.5 to 19.5) and 3.2 (2.5 to 8.9) ng/ml,
respectively. PSA decreased by a median of 3.1% at
the next annual visit in men with no biopsy, and by
a median of 3.6% in those who had 1 or more nega-
tive biopsies. In contrast, for men eventually diag-
nosed with prostate cancer PSA increased by a me-
dian of 13.6% at the next annual visit (p 0.0002 for
both comparisons to other groups).
Fluctuation of the DRE result from abnormal to
normal greatly exceeded that of PSA. Approximately
70% of abnormal DREs were normal the following
year (table 3). Even of the 11 instances of an abnor-
mal DRE with 1 subsequent DRE available before a
prostate cancer diagnosis the DRE reverted to nor-
mal the next year in 8 (72.7%). An abnormal DRE
was followed by 2 and 3 consecutive annual normal
DREs 69.1% and 68.0% of the time, respectively, in
men who had no biopsy performed during followup,
and 50.5% and 42.4% of the time, respectively, in
Table 1. Participant characteristics
No
No. pts 2,272
Median pt age at entry (range) 56.0
No. race/ethnicity (%):
White 1,213
Black 285
Hispanic 759
Other† 15
No. first degree family members with prostate Ca (%):
No 1,866
Yes 406
No. PSAs during followup (%):
2 555
3 469
4 345
5 312
6 or More 591
No. abnormal DREs during followup (%):
0 Abnormal 1,895
1 145
2 or More 41
Not performed or result unknown 191
No. PSAs 2.5 ng/ml or greater during followup (%):
0 1,806
1 195
2 107
3 67
4 43
5 31
6 or More 23
* Of patients with prostate cancer 6 had 1 prior negative biopsy and 3 had 2 pr
† American Indian, Asian or Hawaiian/Pacific Islander.men who had 1 or more negative biopsies duringfollowup. Even among men eventually diagnosed
with prostate cancer in the majority of instances an
abnormal DRE was followed by 2 or 3 consecutive
yearly normal DREs (table 3).
Combining PSA and DRE to indicate a positive
result if PSA was 2.5 ng/ml or greater, or DRE was
abnormal did not improve stability, but rather
showed similar but worse characteristics than the
PSA 2.5 ng/ml criterion. For example, in the group of
men with no biopsy performed in the study, in 234 of
817 (28.6%) instances of a positive combined test the
test reverted to negative the next year. In the same
group of men in 121 of 505 (24.0%) instances of a
positive combined test the next 2 annual tests were
negative and in 63 of 299 (21.1%) instances of a
positive combined test (where there were at least 3
consecutive annual followup tests) the next 3 annual
consecutive tests were all negative.
DISCUSSION
Serum PSA and DRE are the most commonly used
tools for prostate cancer screening. Results from this
study highlight the flaws of screening approaches
that use highly variable tests. Previous studies have
1 or More Neg Biopsies Prostate Ca*
221 85
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.2) 25 (11.3) 22 (25.9)
.7) 44 (19.9) 8 (9.4)
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.4) 114 (51.6) 58 (68.2)
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YEARLY VARIATION IN PROSTATE SPECIFIC ANTIGEN2074Eastham et al evaluated 972 participants in the
Polyp Prevention trial, all without prostate biopsy
and with unknown prostate cancer status, followed
for 4 years as part of a study that did not screen for
prostate cancer.7 Outcome measures included an ab-
normal test based on a PSA greater than 4 ng/ml, a
PSA greater than 2.5 ng/ml, a PSA above the age
specific cutoff, a PSA from 4 to 10 ng/ml and a
free-to-total PSA ratio of less than 0.25 ng/ml, and a
PSA velocity greater than 0.75 ng/ml per year. They
found that prostate biopsy would have been recom-
mended in 21% of participants with a PSA greater
than 4 ng/ml and in 37% with a level higher than 2.5
ng/ml. Among men with an abnormal PSA a high
proportion had a normal PSA at 1 or more subse-
quent visits during 4 years of followup, 44% had a
PSA greater than 4 ng/ml and 40% had a PSA
greater than 2.5 ng/ml. Based on these findings the
authors concluded that an increased PSA should be
confirmed several weeks later before proceeding
with prostate biopsy. A limitation of their study was
the lack of biopsy data on men in whom an increased
PSA developed. In contrast, the current study eval-
uated the roles of PSA as well as DRE in a prospec-
tive cohort in which subjects with increased PSA
and/or abnormal DRE underwent prostate biopsy.
Despite the inherent differences in these patient
populations, the findings are strikingly similar. In
our study approximately 23% and 40% of men in the
Table 2. PSA results after an increase of 2.5 ng/ml or greater
No Biopsy
No. (%) 1
or More
Neg Biopsies
Prostate
Ca
Next consecutive PSA after increased
PSA:*
Not increased 173 (23.3) 61 (17.3) 6 (8.8)
Increased 571 (76.7) 292 (82.7) 62 (91.2)
Next 2 consecutive PSAs after
increased PSA:†
Both not increased 90 (19.5) 29 (11.1) 0 (0.0)
Both increased 312 (67.5) 194 (74.0) 26 (86.7)
First not increased, second increased 28 (6.1) 14 (5.3) 3 (10.0)
First increased, second not increased 32 (6.9) 25 (9.5) 1 (3.3)
Next 3 consecutive PSAs after
increased PSA:‡
All 3 not increased 50 (17.5) 17 (9.5) 0 (0.0)
All 3 increased 165 (57.9) 117 (65.4) 8 (88.9)
Only 1 increased 35 (12.3) 33 (18.4) 1 (11.1)
Only 2 increased 35 (12.3) 12 (6.7) 0 (0.0)
* Number of increased PSAs (participants) with at least 1 subsequent PSA
required to be included in analysis was 744 (368), 353 (124) and 68 (40) for the no
biopsy, 1 or more prior biopsy and prostate cancer groups, respectively.
† Number of increased PSAs (participants) with at least 2 subsequent PSAs
required to be included in analysis was 462 (246), 262 (106) and 30 (22) for the
respective groups.
‡ Number of increased PSAs (participants) with at least 3 subsequent PSAs
required to be included in analysis was 285 (168), 179 (82) and 9 (7) for the
respective groups.no biopsy group had a PSA decrease to less than 2.5and 4.0 ng/ml, respectively, the next year after the
increased PSA, compared to 26% and 30% in the
study by Eastham et al.7 Although the rate of PSA
decreasing to less than the cutoff level decreased,
with each additional year of followup it remained
significant from 23.3% at 1 year to 19.5% at 2 years
and 17.5% at 3 years in the no biopsy group. The
variability in the DRE results on a yearly basis in
this study confirms previous reports of the unreli-
ability and interobserver variability of DRE as a
screening tool for prostate cancer.10–12 Adding DRE
to PSA decreased the performance for prostate can-
cer screening compared to PSA alone while improv-
ing it compared to DRE alone.
These data confirm that PSA and DRE, alone or
in combination, have significant annual variability,
making it difficult to justify their role as the only
recommended screening tools for prostate cancer.
The unreliability of PSA and DRE testing was seen
even in patients diagnosed with prostate cancer, a
finding in agreement with observations from prior
studies of active surveillance for localized prostate
cancer.13,14
Our results have implications for the ways PSA
and DRE are viewed as screening tools for prostate
cancer. Based on these results it is reasonable to
repeat PSA and DRE tests before recommending
prostate biopsy. The timing of the repeat test would
be a flexible decision between clinician and patient.
If there was significant concern, it could be per-
Table 3. DRE results after an abnormal DRE finding
No Biopsy
No. (%) 1
or More
Neg Biopsies Prostate Ca
Next DRE after abnormal DRE:*
Normal 115 (69.7) 76 (67.3) 8 (72.7)
Abnormal 50 (30.3) 37 (32.7) 3 (27.3)
Next 2 DREs after abnormal
DRE:†
Both normal 67 (69.1) 46 (50.5) 5 (62.5)
Both abnormal 12 (12.4) 8 (8.8) 0 (0.0)
First normal, second abnormal 7 (7.2) 12 (13.2) 2 (25.0)
First abnormal, second normal 11 (11.3) 25 (27.5) 1 (12.5)
Next 3 DREs after abnormal
DRE:‡
All 3 normal 34 (68.0) 25 (42.4) 3 (60.0)
All 3 abnormal 2 (4.0) 1 (1.7) 0 (0.0)
1 Abnormal 2 (4.0) 11 (18.6) 1 (20.0)
2 Abnormal 12 (24.0) 22 (37.3) 1 (20.0)
* Number of abnormal DRE findings (participants) with at least 1 subsequent DRE
required to be included in analysis was 165 (138), 113 (75) and 11 (10) for the no
biopsy, 1 or more prior biopsy and prostate cancer groups, respectively.
† Number of abnormal DRE findings (participants) with at least 2 subsequent DREs
required to be included in analysis was 97 (83), 91 (62) and 8 (7) for the 3
respective groups.
‡ Number of abnormal DRE findings (participants) with at least 3 subsequent DREs
required to be included in analysis was 50 (46), 59 (39) and 5 (5) for the 3
respective groups.
YEARLY VARIATION IN PROSTATE SPECIFIC ANTIGEN 2075formed earlier, perhaps within a few weeks. If there
was less concern, with less increased PSA levels, a
less concerning DRE or an abnormal DRE accompa-
nying a low PSA, it might be reasonable to repeat
the test in 6 to 12 months. Performing confirmatory
PSA and DRE tests would most likely improve spec-
ificity of prostate cancer screening. Conversely, data
from the Prostate Cancer Prevention Trial have
shown that PSA is a continuous and not a dichoto-
mous marker for prostate cancer detection.15,16 As
such, even if the PSA is repeated and decreases to
less than the cutoffs of 2.5 or 4 ng/ml, there is still a
risk of prostate cancer and of high grade disease.
One approach that would improve the current
screening paradigm is to use a risk based, indi-
vidualized approach to prostate cancer detection via
risk calculators and nomograms, which estimate a
person’s risk of biopsy detectable prostate cancer
incorporating PSA and DRE, augmenting their pre-
dictive usefulness by including age, race, family his-
tory of prostate cancer, history of a prior negative
biopsy, the presence of lower urinary tract voiding
symptoms, free-to-total PSA ratio, and new biomark-
ers for prostate cancer as they are discovered and
validated.17,18
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YEARLY VARIATION IN PROSTATE SPECIFIC ANTIGEN2076EDITORIAL COMMENTAnkerst et al have further demonstrated the limita-
tions of a single PSA value by looking at a serially
screened cohort of men in a community based pros-
tate cancer screening study. The principal finding
was that among men with a PSA of 2.5 ng/ml or
greater not undergoing biopsy, nearly a quarter re-
verted to a PSA of less than 2.5 ng/ml at the next
year’s screen. Numbers were similar for men with a
history of a negative biopsy where nearly 20% re-
verted to a normal PSA. While the majority of men
experienced a return to abnormal levels, nearly 20%
and 10% of men in the unbiopsied and negative
biopsy cohorts, respectively, continued to have nor-
mal PSA levels for up to 3 years after the increased
PSA. These serial screening data confirm previous
studies that showed significant annual variation in
PSA (reference 7 in article).
While clinicians can take some comfort in know-
ing that some increased PSA values will decrease to
normal levels on followup, this trend may not sub-
stantially decrease the risk of harboring prostate
cancer. Nearly a quarter of men exhibiting a de-
creasing PSA pattern in a similar study were sub-
sequently diagnosed with prostate cancer and a
substantial number of these men had aggressive
cancers.1 Appropriate vigilance must be main-REFERENCEIf a single PSA value must be considered a point
on a continuum of risk or as one of a fluctuating set
of values, how are clinicians to use PSA to determine
a patient’s risk of prostate cancer at a given point in
time (reference 16 in article)? The authors suggest
using PSA as a single component of a comprehensive
risk determination, factoring in other variables such
as family history, race and previous biopsy data.
This is a valid approach but the wide range of pre-
dictions and variables used in the various iterations
of prostate cancer risk prediction models suggests
that this approach needs further refinement. Addi-
tionally, this study demonstrates the difficulties in
using PSA as a sole tool for prostate cancer screen-
ing and indicates that we need to continue our
search for better biomarkers of risk.
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